Leila Arabi is an Assistant Professor of Pharmaceutical Nanotechnology at the School of Pharmacy in Iran. She received her Pharm.D. and Ph.D. degrees (summa cum laude) from the School of Pharmacy, Mashhad University of Medical Sciences (MUMS), Iran in 2009 and 2015. She had a one-year Ph.D. internship during 2012-2013 at the University Hospital Basel, Switzerland. Following her visit to some labs and meetings with academics in the US and Europe, she relocated back to Iran. Her research is focused on developing nanoscale drug delivery systems with particular emphasis on developing liposomes for targeted drug delivery, combination therapy, cancer immunotherapy, vaccines, and gene therapy. Her research has been recognized with awards in the national and international nanomedicine and drug delivery conferences.
Since 2019, she had been the “Communication Chair” of the Immuno-Delivery (ID) Focus group and the Ambassador of the Young Scientist Committee (YSC) of CRS. In 2023, she has been selected to join the YSC as a member. Recently, she joined the Editorial Board of the Journal of Controlled Release (JCR), Drug Delivery and Translational Research (DDTR). She is also serving as the Assistant Editor of the Iranian Journal of Basic Medical Sciences (IJBMS).
Leila’s goal as an Assistant Professor with a demonstrated history of working in Pharmacy & health care is to link the fields of Pharmaceutical Nanotechnology to cancer Biology and immunology to improve the therapeutic efficacy of conventional cancer therapies. She is also particularly interested in empowering the role of WOMEN in science and gender parity in STEM fields
